105 related articles for article (PubMed ID: 38713943)
1. Kaempferol efficacy in metabolic diseases: Molecular mechanisms of action in diabetes mellitus, obesity, non-alcoholic fatty liver disease, steatohepatitis, and atherosclerosis.
Yao YX; Yu YJ; Dai S; Zhang CY; Xue XY; Zhou ML; Yao CH; Li YX
Biomed Pharmacother; 2024 Jun; 175():116694. PubMed ID: 38713943
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological effects of polydatin in the treatment of metabolic diseases: A review.
Luo J; Chen S; Wang L; Zhao X; Piao C
Phytomedicine; 2022 Jul; 102():154161. PubMed ID: 35636169
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence.
Xu X; Yi H; Wu J; Kuang T; Zhang J; Li Q; Du H; Xu T; Jiang G; Fan G
Biomed Pharmacother; 2021 Jan; 133():110984. PubMed ID: 33186794
[TBL] [Abstract][Full Text] [Related]
4. Ugonin J improves metabolic disorder and ameliorates nonalcoholic fatty liver disease by regulating the AMPK/AKT signaling pathway.
Chang TC; Chiou WC; Lai WH; Huang HC; Huang YL; Liu HK; Liang YC; Huang C
Pharmacol Res; 2021 Jan; 163():105298. PubMed ID: 33220422
[TBL] [Abstract][Full Text] [Related]
5. Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway.
Li N; Yin L; Shang J; Liang M; Liu Z; Yang H; Qiang G; Du G; Yang X
Biomed Pharmacother; 2023 Sep; 165():115113. PubMed ID: 37418974
[TBL] [Abstract][Full Text] [Related]
6. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.
Ampuero J; Aller R; Gallego-Durán R; Banales JM; Crespo J; García-Monzón C; Pareja MJ; Vilar-Gómez E; Caballería J; Escudero-García D; Gomez-Camarero J; Calleja JL; Latorre M; Albillos A; Salmeron J; Aspichueta P; Lo Iacono O; Francés R; Benlloch S; Fernández-Rodríguez C; García-Samaniego J; Estévez P; Andrade RJ; Turnes J; Romero-Gómez M;
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1260-1270. PubMed ID: 30353552
[TBL] [Abstract][Full Text] [Related]
7. Kaempferol as a therapeutic agent in Alzheimer's disease: Evidence from preclinical studies.
Dong X; Zhou S; Nao J
Ageing Res Rev; 2023 Jun; 87():101910. PubMed ID: 36924572
[TBL] [Abstract][Full Text] [Related]
8. Kaempferol: A Dietary Flavonol in Alleviating Obesity.
Nejabati HR; Nikzad S; Roshangar L
Curr Pharm Des; 2023; 29(20):1547-1556. PubMed ID: 37537778
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Effect of Curcumin on Metabolic Diseases: Evidence from Clinical Studies.
Zeng Y; Luo Y; Wang L; Zhang K; Peng J; Fan G
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834734
[TBL] [Abstract][Full Text] [Related]
10. Multitarget and promising role of dihydromyricetin in the treatment of metabolic diseases.
Tong H; Zhang X; Tan L; Jin R; Huang S; Li X
Eur J Pharmacol; 2020 Mar; 870():172888. PubMed ID: 31866404
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Importance of Kaempferol in the Treatment of Cancer through the Modulation of Cell Signalling Pathways.
Qattan MY; Khan MI; Alharbi SH; Verma AK; Al-Saeed FA; Abduallah AM; Al Areefy AA
Molecules; 2022 Dec; 27(24):. PubMed ID: 36557997
[TBL] [Abstract][Full Text] [Related]
12. Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.
Mahmoudi A; Butler AE; Jamialahmadi T; Sahebkar A
Biomed Res Int; 2021; 2021():3654660. PubMed ID: 34988225
[TBL] [Abstract][Full Text] [Related]
13. Old wine in new bottles: Kaempferol is a promising agent for treating the trilogy of liver diseases.
Xiao X; Hu Q; Deng X; Shi K; Zhang W; Jiang Y; Ma X; Zeng J; Wang X
Pharmacol Res; 2022 Jan; 175():106005. PubMed ID: 34843960
[TBL] [Abstract][Full Text] [Related]
14. Anticancer Properties of Kaempferol on Cellular Signaling Pathways.
Sengupta B; Biswas P; Roy D; Lovett J; Simington L; Fry DR; Travis K
Curr Top Med Chem; 2022; 22(30):2474-2482. PubMed ID: 36082856
[TBL] [Abstract][Full Text] [Related]
15. Phytochemicals for the treatment of metabolic diseases: Evidence from clinical studies.
Luo Y; Zeng Y; Peng J; Zhang K; Wang L; Feng T; Nhamdriel T; Fan G
Biomed Pharmacother; 2023 Sep; 165():115274. PubMed ID: 37542856
[TBL] [Abstract][Full Text] [Related]
16. Kaempferol Improves Cardiolipin and ATP in Hepatic Cells: A Cellular Model Perspective in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Sakurai A; Sakurai T; Ho HJ; Chiba H; Hui SP
Nutrients; 2024 Feb; 16(4):. PubMed ID: 38398832
[TBL] [Abstract][Full Text] [Related]
17. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases.
Tillman EJ; Rolph T
Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
19. Natural compounds against nonalcoholic fatty liver disease: A review on the involvement of the LKB1/AMPK signaling pathway.
Omidkhoda N; Mahdiani S; Hayes AW; Karimi G
Phytother Res; 2023 Dec; 37(12):5769-5786. PubMed ID: 37748097
[TBL] [Abstract][Full Text] [Related]
20. Hypothalamus-pituitary-adrenal Axis in Glucolipid metabolic disorders.
Lin Y; Zhang Z; Wang S; Cai J; Guo J
Rev Endocr Metab Disord; 2020 Dec; 21(4):421-429. PubMed ID: 32889666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
